Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Investors are optimistic about Walgreens (WBA) owing to the recent product launches.

Here's Why You Should Hold on to Walgreens Boots (WBA) For Now

A jury trial accusing Walgreens Boots Alliance of contributing to Florida's opioid addiction epidemic was set to begin on Monday after the pharmacy chain opted not to join a multimillion-dollar settlement by other defendants.

Walgreens trial over its part in Florida opioid crisis set to begin

Walgreens Boots Alliance WBA, +1.23% CEO Rosalind Brewer joined the board of Village MD, a privately held network of primary care clinics that Walgreens has invested in. Walgreens announced in October that it would invest $5.2 billion in VillageMD, with the goal of opening 600 Village Medical at Walgreens clinics by 2025.

Walgreens CEO joins VillageMD board

Walgreens' (WBA) new initiative is intended to reduce care gaps and advance care management by providing access to more affordable and convenient services.

Walgreens (WBA) Expands Medical Care Offerings in California

The Health Corner locations are a piece of Walgreens' strategy to become a bigger health care player.

Walgreens expands its medical-care offerings in major California markets

Innovative approach expands access to care management and coordination for Californians through in-store and virtual resources OAKLAND, Calif. and DEERFIELD, Ill.

Blue Shield of California and Walgreens Health Unveil New Health Advisory Service Offering Personalized, Affordable Care

The iShares U.S. Pharmaceuticals ETF is continuing up since March 8th, but it's not too late to hop onto the rally. There still are pharmacy stocks that are attractive buys at current valuations.

Two experts give away their favourite pharmacy stock

Apple

Alphabet

Microsoft

Whenever a new technology changes the way something is done, it tends to ruffle people's feathers. It takes time and effort to build widespread acceptance of an innovation, and the learning curve is rarely smooth.

Why People Love Innovation, but Fear Change

Airbnb

Nextdoor

Pinterest

Spotify

Twitter

This is one of the most widely used platforms in the U.S., but its stock has yet to find much traction.

Down 65%, This Small-Cap Stock Could Be a Home Run for Patient Investors

Philip Morris

AT&T

These well-known companies, which are yielding between 4% and 5.3%, are begging to be bought following the Nasdaq's 22% peak decline.

Nasdaq Bear Market: 3 Brand-Name, High-Yield Dividend Stocks You'll Regret Not Buying on the Dip

Walgreens Boots Alliance Inc.'s ( WBA , Financial) stock appears to be a bit under the weather, with its share price dipping as the pandemic continues to wane.

Walgreens Boots Alliance Looks a Bit Under the Weather

Walgreens Boots Alliance Inc (NASDAQ: WBA) shares continue to trade lower Friday after the company on Thursday reported financial results and reaffirmed soft guidance for low-single digit earnings growth.  Walgreens said fiscal second-quarter revenue increased 3% year-over-year to $33.8.

Walgreens Stock Fell 8% This Week: What Happened?

Strong execution across business segments, led by COVID-19 vaccinations and testing, drove Walgreens' (WBA) fiscal second-quarter top line.

Walgreens Boots (WBA) Q2 Earnings Top Estimates, Margins Up

Walgreens Boots Alliance, Inc. (WBA) CEO Rosalind Brewer on Q2 2022 Results - Earnings Call Transcript

Shares of Walgreens Boots Alliance (NASDAQ: WBA) imploded in the wake of what were otherwise stellar results and guidance because of COVID. The company didn't catch COVID and there weren't any major COVID-related shutdowns which is ultimately the problem.

High-Yielding Walgreens Boots Alliance Goes On Sale

Walgreens surpassed Wall Street expectations in the second quarter thanks to strong demand for COVID-19 tests and vaccines.

COVID tests, vaccines help Walgreens beat expectations on earnings

Walgreens Boots Alliance Inc (NASDAQ: WBA) on Thursday reported market-beating results for its fiscal second quarter. Shares still slid 8.0% as YoY growth and reiterated guidance failed to inspire investor confidence.

Walgreens reports Q2 results: ‘supply chain is improving'

As the world waits for the answer on what Walgreens will do with its U.K.-based Boots unit, the company rode a spike in COVID-19 tests and booster shots to higher-than-expected earnings in the second quarter of fiscal 2022, according to a company press release Thursday (March 31). Walgreens doled out 11.8 million COVID-19 vaccine shots […]

Walgreens' Q2 Performance Buoyed by Rising Demand for COVID-19 Tests and Boosters

Walgreens Boots Alliance Inc's (NASDAQ: WBA) Q2 FY22 sales increased 3% Y/Y to $33.8 billion, up 3.8% on a constant currency basis, beating the consensus of $33.36 billion. Omicron variant of COVID-19 intensified demand for booster shots and tests and drove foot traffic during the.

Why Walgreens Boots Alliance Shares Are Plunging Today

Vipshop Hlds

Investors were left feeling directionless on the last trading day of the quarter.

Why Walgreens and Vipshop Left the Market Mixed Thursday Morning

The shares of blue-chip pharmaceutical name Walgreens Boots Alliance Inc (NASDAQ:WBA) are down 2.6% at $46 this morning, even after the company reported a top- and bottom-line beat for its fiscal second-quarter.

Tepid Full-Year Forecast Sends Walgreens Stock Lower

Walgreens Boots Alliance Inc reported higher-than-expected quarterly profit and sales on Thursday, boosted by a rush for COVID-19 vaccinations and testing during a recent Omicron-led surge in COVID-19 cases.

Walgreens beats estimates on Omicron-led demand for vaccines, tests

The drugstore behemoth delivered adjusted earnings of tk per share

Walgreens Beat Earnings Thanks to Demand for Covid-19 Tests and Vaccines

Walgreens Boots Alliance Inc. WBA, -0.75% shares edged up 0.3% in Thursday premarket trading after it reported fiscal second-quarter profit and sales that beat expectations. The pharmacy retailer reported net income of $883 million, or $1.02 per share, down from $1.026 billion, or $1.19 per share, last year.

Walgreens profit and sales beat Street expectations

Walgreens Boots Alliance shares fell as demand linked to the Covid pandemic slowed somewhat and the company ramps up its investments in health-care services.

News for Walgreens Stock (WBA)